The Cigna Group (CI) fair value analysis

S&P 500 · Updated 2026-09-07

The Cigna Group is a healthcare company that provides health insurance, medical services, and pharmacy benefits to individuals and employers. The company operates globally with a significant presence in the United States and maintains operations in numerous international markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, CI is trading at a 10–25% discount to estimated fair value.

CI currently ranks #34 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $282.52
Sector: Healthcare
12-month range: $244.41–$289.26

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: F
Leverage: Moderate
Margin trend: Contracting
Revenue growth: Strong
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for CI

Our model validated 17 trailing price-to-earnings windows for CI, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $244.41–$289.26.
The 14-day relative strength index sits at a neutral 58.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for CI
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent CI news

TickrTrends' derived news-sentiment signal for CI is currently mixed, computed from recent coverage.

Cigna: I'm Buying What Others Are Ignoring (NYSE:CI) (seekingalpha.com, 2026-08-17)
TickrTrends take: CI trades at a valuation that TickrTrends currently classifies as undervalued within the Healthcare sector, creating a potential disconnect between market pricing and fundamental value that investors focused on valuation metrics may find noteworthy. The investment community's apparent indifference suggested in the headline aligns with opportunities that typically emerge when market participants overlook securities trading below their assessed intrinsic value. Valuation-oriented investors monitoring CI should observe whether the company's financial fundamentals strengthen sufficiently to close any gap between current market pricing and the level implied by its undervalued status.
Cigna's Valuation Gap Still Stands Out (NYSE:CI) (seekingalpha.com, 2026-07-31)
TickrTrends take: CI trades at a valuation level that TickrTrends currently classifies as undervalued within the Healthcare sector. The persistence of a valuation gap suggests the market may not be fully pricing in the company's fundamentals relative to peer comparables in insurance and healthcare services. For valuation-focused investors, monitoring whether this gap narrows would indicate market repricing of CI's worth.
What I Believe Investors Are Missing With Cigna (NYSE:CI) (seekingalpha.com, 2026-07-27)
TickrTrends take: Cigna operates in the Healthcare sector where TickrTrends currently derives an Undervalued verdict for the stock. An article suggesting investors are overlooking aspects of Cigna's investment case aligns with valuation metrics that appear attractive relative to the company's fundamentals. A valuation-focused reader should monitor whether the market begins to recognize the factors discussed in such analysis, as this could influence whether the current undervaluation assessment persists or reverses.

What people are saying

Follow the CI conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for CI in the Healthcare sector shifted toward a more favorable valuation assessment this week. The DCF cross-check band moved from fairly valued to undervalued, while momentum indicators transitioned from a D rating to none, suggesting reduced downward pressure. The current valuation verdict remains Undervalued.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is CI stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), CI is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is CI's TickrTrends verdict?

CI's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does CI compare to other Healthcare stocks?

CI ranks #34 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is CI overbought or oversold?

CI's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

CI vs AVAH · CI vs GEHC · CI vs INCY · CI vs INDV · CI vs LMAT